Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms.
Marie OrliaguetSylvie BoisraméJean-Richard EveillardBrigitte Pan-PeteschMarie-Anne CouturierVincent RebièreGaelle GuillermMarie-Caroline Le Bousse-KerdilesLaurent MiseryEric LippertJean-Christophe IanottoPublished in: EJHaem (2020)